Encoded preps for Dravet launch with $275M round: Finance Report

A $275 million venture round will propel Encoded through a pivotal study and launch preparations as its gene therapy for a rare seizure disorder continues to advance through clinical testing.

A series F syndicate co-led by GV and an undisclosed investor backed Encoded Therapeutics Inc. in the round, which comes about six months after the start-up said it had begun a pivotal trial of ETX101 to treat genetically driven Dravet syndrome. The 30-patient ENDEAVOR Part 2 study is evaluating the therapy in infants and young children aged less than four years...